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Multi-drug resistant tuberculosis (MDR-TB) represents a growing problem for global healthcare 
systems. In addition to 1.3 million deaths in 2018, the World Health Organisation reported 484,000 
new cases of MDR-TB. Isoniazid is a key anti-TB drug that inhibits InhA, a crucial enzyme in the 
cell wall biosynthesis pathway and identical in Mycobacterium tuberculosis and M. bovis. 
Isoniazid is a prodrug which requires activation by the enzyme KatG, mutations in KatG prevent 
activation and confer INH-resistance. ‘Direct inhibitors’ of InhA are attractive as they would 
circumvent the main clinically observed resistance mechanisms. A library of new 1,5 triazoles 
designed to mimic the structures of both triclosan molecules uniquely bound to InhA have been 
synthesised. The inhibitory activity of these compounds was evaluated using isolated enzyme 
assays with 2 (5-chloro-2-(4-(5-(((4-(4-chloro-2-hydroxyphenoxy)benzyl)oxy)methyl)-1H-1,2,3-
triazol-1-yl)phenoxy)phenol) exhibiting an IC50 of 5.6 µM. Whole-cell evaluation was also 
performed, with 11 (5-chloro-2-(4-(5-(((4-(cyclopropylmethoxy)benzyl)oxy)methyl)-1H-1,2,3-
triazol-1-yl)phenoxy)phenol) showing the greatest potency, with an MIC99 of 12.9 µM against M. 
bovis. 
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Tuberculosis (TB) is one the leading global causes of mortality and is currently the world’s 
deadliest infectious disease. In addition to the estimated 1.3 million deaths from TB in 2018, a 
further 0.25 million Human Immunodeficiency Virus-positive (HIV) individuals died as a result 
of co-infection with Mycobacterium tuberculosis.1  
 
The current anti-TB treatment course relies on four drugs: isoniazid (INH), rifampicin (RIF), 
ethambutol (ETH) and pyrazinamide (PZA). The increasing prevalence of multi-drug resistant TB 
(MDR-TB) threatens to undermine the efficacy of this treatment regimen. MDR-TB infections are 
characterised as those displaying resistance to INH and RIF. In 2018, the WHO reported over 
484,000 new MDR-TB infections. Additionally, 13,000 were classified as extensively drug 
resistant (XDR-TB) meaning they were also insensitive to any fluoroquinolone and at least one of 
the second-line injectable drugs.2-4 This emerging resistance is further exacerbated by the lack of 
novel drugs coming through the pipeline, with only three new drugs entering the clinic in the last 
40 years (delamanid, pretomanid and bedaquiline).5, 6  
 
Mycobacteria’s dense and complex cell wall represents one of the main reasons for the hardiness 
of the bacteria. The relative impermeability of the Mycobacterium cell wall can primarily be 
attributed to its mycolic acid component. This waxy layer consists of long chain (~C50-90) α-
branched, β hydroxylated fatty acids. This barrier not only hinders the passage of small molecules 
into the cell, but also provides protection from the host’s immune response.7  
 
The frontline drug INH elicits its biological effects through disruption of the mycolic acid 
biosynthetic pathway, via inhibition of the enzyme InhA.8 InhA is a nicotinamide adenine 
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dinucleotide (NADH)-dependent enoyl acyl carrier reductase which catalyses the chemoselective 
reduction of its 2-trans-enoyl-ACP substrate. The enzyme has an identical amino acid sequence 
(and hence structure) in M. tuberculosis and M. bovis, the main causative agents of tuberculosis in 
humans and dairy cattle respectively.  INH is actually a pro-drug which requires activation before 
it can inhibit mycolic acid biosynthesis (Figure 1). 
 
Figure 1. A) The structure of key anti-TB drug INH and the pathway through which it elicits its 
biological effects. B) Crystal structure of the INH-NAD adduct bound to InhA showing how the 
adduct blocks the substrate binding cavity (PDB: 1ZID). 
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Initially, the catalase peroxidase enzyme, KatG converts INH to its corresponding isonicotinyl 
radical species. Upon activation, INH forms a covalent adduct with the co-factor which in-turn 
blocks the active site, preventing substrate binding.9, 10 A single KatG point mutation, S315T, is 
sufficient to render INH inactive and has been implicated in up to 95% of INH resistant clinical 
isolates examined.11, 12 With this in mind, the development of ‘direct InhA inhibitors’ represents a 
compelling approach for the discovery of new anti-TB drugs.13-16 Direct inhibitors refer to 
compounds which, unlike INH, do not require prior activation to exert their inhibitory effects. 
These inhibitors would circumvent the current resistance mechanisms and could be used to treat 
resistant infections.  One such direct inhibitor is the small molecule, broad spectrum antibiotic 
triclosan (TCS, Figure 2.). TCS is a moderate, reversible inhibitor of InhA and has formed the 




Crystallographic studies have highlighted an unusual binding trait for the TCS:InhA complex. Two 
molecules of TCS are able to occupy the InhA active site (PDB: 1P45), something not replicated 
in homologous proteins from other bacteria.19 Inspection of the crystal structure reveals that the 
TCS2 molecule lies only ~ 4.2 Å away from the TCS1 moiety (Figure 3). This suggests that 
through modification of the B ring, it may be possible to obtain TCS-derivatives which are capable 
of occupying both binding sites through a single molecule, possibly producing a more potent and 
selective inhibitor for InhA that also benefits from a lower entropic cost in binding.  
Figure 2. The structure of TCS and the denotation of the A and B rings. 
 6 
 
Figure 3. X-ray structure showing two TCS molecules bound to the InhA active site. Residues are 
shown with orange carbons, NAD+ is shown with teal carbons, TCS are shown with yellow 
carbons. H-bonds are shown by dashed-black lines. (PDB: 1P45) 
 
In this article, we report the in silico design, synthesis and characterization of a series of novel 
TCS derivatives bearing a 1,5-triazole group attached to the B-ring. These compounds were 
designed to occupy both of the TCS binding sites observed in the crystal structure. Biological 




The first step in designing TCS analogues which could anchor into both binding sites was 
identifying a suitable linker to connect the two fragments. It was vital that the linker did not disrupt 
the experimentally observed binding mode for TCS1, while at the same time the linker geometry 
had to direct the attached fragment back into the TCS2 binding region. To this end, it was thought 
that a disubstituted 1,2,3-triazole ring would be an appropriate motif. It was hoped that the rigid 
nature of the triazole scaffold would direct any substituent group back into the TCS2 binding site. 
This notion was explored using the Genetic Optimisation for Ligand Docking (GOLD) platform.20 
Two test compounds, a 1,4 and a 1,5-triazole, were designed and both were docked into the InhA 
active site (PDB: 1P45). The binding poses obtained are shown below in Figure 4.  
 
Figure 4. The structures of two basic TCS-triazole compounds and their docking poses generated 
by GOLD, this shows the overlap between the designed compounds and the two TCS moieties 
found in the active site. (PDB: 1P45) 
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As demonstrated in Figure 4, when the two fragments are connected through a 1,5-triazole unit 
(2), the TCS-like binding mode is retained, and the secondary fragment occupies the same space 
as the TCS2 moiety. The 1,4-triazole (1) did not generate a suitable structure and the B-ring 
modification resulted in a perturbation of the TCS binding mode, including loss of the key 
hydrogen bonding network shown in Figure 3. This is of particular importance as this H-bonding 
network is conserved amongst most potent InhA inhibitors, with the exception of the methyl-
thiazole compound class.19, 21-23   
 
With this information in hand, a range of compounds bearing a single aromatic ring attached 
through the 1,5-triazole motif were also designed (Figure 5). Previous studies have demonstrated 
that the B-ring Cl atoms are not required for potent InhA inhibition and so they were removed in 
an attempt to control the lipophilicity of the target compounds.18, 24 




Scheme 1. Reagents and conditions: a) K2CO3, DMF, 130 °C, 18 h, 95%; b) BBr3, CH2Cl2, 0 °C -
> r.t., N2, 3 h, 89%; c) Zn, NH4Cl, MeOH, r.t., 18 h, 75%; d)
 tBuONO, TMSN3, ACN, 0 °C  -> r.t., 
3 h, 80% 
 
The synthesis of biaryl azide 16 is shown in Scheme 1. The initial biaryl scaffold was assembled 
through an SNAr reaction using 1-fluoro-4-nitrobenzene and 4-chloro-2-methoxy phenol, 
furnishing 13 in near quantitative yields. Sequential BBr3 mediated ether demethylation and nitro 
reduction with Zn/NH4Cl gave amine 15 in a good yield over two steps. Finally, functional group 







Scheme 2. Reagents and conditions: a) K2CO3, DMF, 130 °C, 18 h, 92%; b) AcOH, HBr, 140 °C, 
18 h, 38%; c) MOMCl, DIPEA, CH2Cl2, r.t., 18 h, 86%; d) NaBH4, MeOH, 0 °C -> r.t., 4 h, quant.; 
e) NaH, propargyl bromide, DMF, 0 °C -> r.t., 18 h, 79%; f) 6 M HCl (aq), MeOH, 70 °C, 2 h, 
90% 
The synthesis of alkyne-bearing TCS fragment 22 is shown in Scheme 2. The biphenyl scaffold 
17 was assembled in a similar fashion to the corresponding nitro-compound 13, in a good yield. 
Cleavage of the methyl ether was performed using AcOH and HBr at elevated temperatures, 
generating 18 in a modest yield. This method was used due to the instability of the benzaldehyde 
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group that was observed when demethylation was attempted with BBr3. The newly exposed phenol 
was then reprotected using MOMCl in a good yield. Benzaldehyde 19 was reduced to its 
corresponding benzyl alcohol using NaBH4 before etherification using NaH and propargyl 
bromide, giving ether 21 in good yield over two steps. The phenol functionality was then unmasked 
using 6 M HCl to furnish the alkyne-bearing TCS fragment 22 in a near quantitative yield.  
 
Selective formation of 1,5-triazoles can be achieved through the use of ruthenium catalysed azide-
alkyne cycloaddition (RuAAC) and has seen increasing numbers of examples in the literature over 
the last decade.26, 27 With 22 and 16 in hand, the 1,5-triazole motif was assembled via an RuACC, 
using Cp*RuCl(PPh3)2 in 1,4-dioxane (Scheme 3). 
 
 
Scheme 3. Reagents and conditions: a) Cp*RuCl(PPh3)2, 1,4-dioxane, 60 °C, N2, 18 h, 17% 
 
The RuAAC reaction furnished 2 in an acceptable yield, following reverse phase high performance 
liquid chromatography (HPLC) purification. The identity of the product was confirmed as a 1,5 
triazole using the NMR methods previously discussed by Creary et al.28  Following the synthesis 
of 2, the aforementioned truncated analogues were synthesised from the azide 16 and alkyne 
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fragments (23-32, synthesis detailed in supplementary information), using the same RuAAC 
conditions, giving the desired 1,5-triazoles in moderate yields after HPLC (Scheme 4). 
 
Scheme 4. Reagents and conditions: a) Cp*RuCl(PPh3)2, 1,4-dioxane, 60 °C, N2, 18 h, 5-33% 
An isolated enzyme assay was used to assess the inhibitory properties of the compounds 
synthesised. Initial screening was performed at 50 µM with 150 nM of InhA from M. tuberculosis 
using a standard UV absorbance assay that has been widely used in the identification of novel 
InhA inhibitors. Assays were performed using 2-trans-octenoyl CoA as a mimic for the enzyme’s 






Table 1. Inhibitory data for compounds tested using an isolated enzyme assay, conducted at 50 
µM. GOLD fitness scores are also included for each compound. Inhibition values are an average 
of duplicate assays.  
Compound GOLD Fitness Score Inhibition / % 
2 87.7 100 
3 65.2 12 
4 73.5 38 
5 77.8 72 
6 74.0 6 
7 69.0 13 
8 76.7 44 
9 73.2 0 
10 75.6 47 
11 80.7 11 
12 83.6 42 
TCS 70.8 92 
 
The inhibitory activity observed for compounds 2 – 12 is summarized in Table 1, these results 
indicate a number of the compounds tested showed moderate inhibition of InhA at 50 µM. Moving 
from H->Me->iPr (3->5) results in increased inhibition, however, the introduction of a tBu (6) 
leads to a significant reduction in enzyme inhibition, suggesting that such a bulky group results in 
major clashes with the protein. This loosely correlates with the fitness scores, with compound 6 
showing a lower fitness score than 5. The possibility that this region is size sensitive is further 
supported by the fact that compounds 8, 10 and 12, all of which bear relatively small R groups, 
show moderate inhibition. The most potent compound was 2 which showed a total reduction in 





The predicted binding mode for 2 is shown in Figure 6. This binding pose shows how the ‘front’ 
TCS fragment is able to engage the NAD+ co-factor and Tyr158 through the key hydrogen bonding 
network. The 1,5-triazole architecture directs the second TCS fragment back towards the substrate 
binding loop, where a number of hydrophobic contacts are made. Further evaluation of 2 showed 
it exhibits an IC50 of 5.6 ± 0.8 µM (n = 3). This represents a modest improvement on TCS (IC50 = 




Figure 6. Predicted binding mode for 2. Residues are shown with orange carbons, NAD+ is shown 
with teal carbons, 2 is shown with yellow carbons. H-bonds are shown by dashed-black lines. 
(PDB: 1P45) 
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Whole-cell evaluation of all 12 compounds was undertaken to investigate the correlation between 
isolated enzyme activity and whole-cell efficiency. Compounds were initially assessed for growth 
inhibition against Mycobacterium bovis at a fixed concentration of 40 µM. Results are shown in 
Table 2. 
Table 2. Inhibition data for all compounds tested against Mycobacterium bovis at 40 µM, results 












Disappointingly, the isolated assay potency of 2 towards InhA did not correlate to whole-cell 
potency. This could possibly be attributed to inability to pass through the dense mycobacterial cell 
wall, or other factors such as efficient transport by efflux pumps.31, 32 It is possible that 
reintroducing the ortho Cl atom to the B-ring (giving a compound with a cLogP 6.61) could result 
in greater whole-cell potency, although the previous QSAR study by Sivaraman et al.24 indicate 
that this chlorine is not critical, this is something that will be explored going forward. Of the 12 
Compound Inhibition / % cLogP 
2 20 5.80 
3 3 5.11 
4 -6 5.43 
5 15 5.89 
6 20 6.11 
7 0 4.37 
8 40 5.03 
9 4 5.61 
10 19 6.09 
11 99 6.07 
12 23 5.95 
TCS 70 4.98 
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compounds tested, 11 showed the greatest potency, with 99% growth inhibition at 40 µM. This 
compound was subject to further evaluation to determine its MIC99 (Figure 7).  
Figure 7. MIC99 curve for 11. 
Compound 11 displayed an MIC99 of 12.9 ± 5.0 µM (6.2 µg mL
-1, n. = 3). Clearly there is a 
disconnect between the activity of 11 in isolated enzyme assays and its performance in the whole-
cell screening tests. This suggests that 11 has other off-target sites within the bacteria which result 
in significant potency. At high concentrations TCS has been reported to act as a mitochondrial 
uncoupling, cell membrane permeator and to cause disruption to both lipid and protein 
biosynthesis.18 Further work will be required to elucidate the main biological target(s) of 11.  
As previously mentioned, TCS has formed the basis for a number of SAR studies towards potent 
inhibitors of InhA. The most common modification is replacement of the A-ring Cl atom with 
various hydrophobic groups. Comprehensive B-ring modifications remain relatively 
unexplored.33-35 Two examples of previously disclosed direct InhA inhibitors are shown in Figure 
8.35, 36 Compound 2 is similar in concept to 33, recently reported by Rodriguez et al., which sought 
to merge two TCS molecules in a macrocyclic arrangement. Compounds 33 and 2 have similar 






Figure 8. The structures of previously disclosed TCS-based inhibitors of InhA and their biological 
activities. 
In terms of MIC99 data, in this study, 11 showed significant potency in whole-cell assays with an 
MIC99 value of 12.9 µM, this value is approaching the MIC99 of 34 (6.6 µM). It is possible that, 
following the elucidation of 11’s target, its potency could be further improved to the match or 
exceed the activity of 34. 
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The rational in silico design, synthesis and characterization of a novel series of triazole-bearing 
TCS derivatives is reported. These compounds were designed to exploit the large volume of the 
InhA active site and occupy both TCS binding sites observed in the PDB: 1P45 crystal structure. 
Docking results suggested that these compounds would be able to occupy both of the TCS binding 
regions, possibly giving a direct inhibitor of Mycobacterial InhA with higher affinity and 
selectivity than TCS. Enzyme assays on purified M. tuberculosis InhA were used to evaluate the 
compounds synthesized, with the most potent showing an IC50 of 5.6 ± 0.8 µM which is similar to 
that of TCS. Whole-cell evaluation against M. bovis showed the most potent compound was 11 
which displayed an MIC of 12.9 ± 5.0 µM, despite only showing 11% inhibition at 50 µM in 




Experimental details are reported including: full synthetic procedures and characterization data for 
all compounds. NMR spectra and analytical HPLC traces of key compounds 2 and 11 are included. 
Methods for protein expression, purification, isolated enzyme activity assay conditions, IC50 curve 




T.A. synthesized all compounds, performed enzyme assays, analysed data and wrote the 
manuscript. M.L. expressed & purified InhA and performed enzyme assays. A.L. performed 
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